Optimum Perspectives

In this Optimum Perspectives celebratory episode for International Day of Women & Girls in Science, hear from five influential women on how they broke down gender barriers to succeed in the life science industry. Chaired by esteemed journalist Lisa Urquhart, hear guest speakers Renee Aguiar-Lucander of Calliditas, Lene Gerlach of EIR Ventures & WiLD, Bita Sehat of Trill Impact,&n...

Happy 1st birthday to the Optimum Perspectives Podcast! Since launching, 1000s of listens have grown the show into an excellent hub of intel from top tier life science guests. Listen now to our anniversary special, where Optimum's Mary Clark, Nick Bastin and Eva Haas discuss the findings of our insightful European Life Sciences Investor survey! Hosted on Acast. See acast.com/privacy for more infor...

Hear Vicore Pharma’s CEO, Ahmed Mousa speak to Optimum's Richard Staines on their new treatment for Idiopathic Pulmonary Fibrosis (IPF), C21. It aims to improve available treatments for patients of IPF by halting the progression of fibrosis and has the aim of restoring lung function. Hosted on Acast. See acast.com/privacy for more information.

In this insightful and emotional podcast episode, the co-founder of Ariana Smiles - a Special Named Fund at CCLG UK, Stephanie Seales Gabbitas shares her mission to improve the lives of children diagnosed with Leukaemia by raising funds for research into precision oncology medicine. Hosted on Acast. See acast.com/privacy for more information.

There is a lack of effective treatments for Cutaneous T-Cell Lymphoma (CTCL) – in this podcast episode Jason Loveridge, CEO of 4SC, talked to Optimum Strategic Communications’ Eva Haas about the Company’s potential new maintenance therapy Kinselby (resminostat). 4SC is a late-stage biotech improving lives for patients suffering with advanced-stage Cutaneous T Cell Lymphoma (CTCL). It has developed...

Optimum celebrated its 15th Annual Healthcare Investor Conference – marking its crystal anniversary – and what a sparkler it was! In the latest episode of Optimum Perspectives Podcast, Richard Staines talks through the top takeaways from the October event with special testimonials from our guests. Hosted on Acast. See acast.com/privacy for more information.

Episode 9 of Optimum Perspectives Podcast features Optimum's Richard Staines and Eva Haas, who discuss the hot areas for investment in the shifting biotech market – including antibody-drug conjugates, smart radiotherapies, mRNA and immune-oncology. Want us to explore a topic further? Let us know! Hosted on Acast. See acast.com/privacy for more information.

Alchemab aims to revolutionise drug discovery with a novel alternative to the classic “choose a target” approach.  Alchemab specifically looks to identify shared antibodies from people who have shown resilience to disease – the unexpectedly well. The company then uses its proprietary technology to identify which targets these antibodies are binding to, and what diseases these targets are asso...

No-one is likely to forget the tragic events of 2020 and one company leading efforts to prepare for the next pandemic is Poolbeg Pharma . Optimum Strategic Communications’ Richard Staines interviewed CEO Jeremy Skillington to find out how Poolbeg is using AI to expedite discovery of new flu drugs. Poolbeg is working on a drug that aims to block some of the worst effects of influenza, neutralising...

A much-anticipated new potential drug for COPD moved a step closer to the market after Verona Pharma submitted its New Drug Application to the U.S. FDA, seeking approval of ensifentrine as a maintenance therapy. In its latest podcast, Optimum Strategic Communications caught up with Chris Martin, Senior Vice President of Commercial, who discussed how the company plans to launch this potential...

Today’s funding environment for small biotechs is tough. Valuations are down and money is tighter than it used to be – both for publicly listed and privately held firms.   In these circumstances, obtaining the right backing – both in terms of finance and managerial advice – is more important than ever.  In the fifth Optimum Perspectives podcast experienced investor Søren Møller talk...

How do you take a tiny private Swedish biotech and turn it into a successful, publicly-listed company operating on both sides of the Atlantic, in just six years? Listen to Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, tell Optimum’s Richard Staines how they brought TARPEYO, the first FDA-approved drug for the rare kidney disease primary IgA nephropathy, to market. She describes her ‘incre...

In this episode, our in-house IR expert, and ex-Fund Manager Eva Haas interviewed Dan Mahony, Chairman of the BioIndustry Association (BIA), following his appointment as UK Life Sciences Investment Envoy to hear his plans for championing the UK’s Life Sciences industry. Read the insight piece here: An interview with Dan Mahony, UK Government Life Sciences Envoy by Optimum’s Eva Haas https://www.op...

Stress urinary incontinence (SUI) is a common and debilitating problem for many women, particularly after childbirth or in later years.  Yet, despite this, treatment options are limited, held back by a lack of research into medical products focused on women’s health.  Versameb , hopes to change this with a novel mRNA therapy that rebuilds the urinary sphincter and is about to enter clini...

Our host Richard Staines , Account Director at Optimum, discusses the latest clinical findings from inobrodib, an oral cancer therapy developed by the UK biotech CellCentric . In our first episode, we hear from Jan Ross, a patient who discusses the pressing need for new therapies for multiple myeloma with fewer side effects. We also talked to top cancer experts – Tim Somervaille of the Christie Ho...